Search

Displaying results 1131 - 1140 of 7604 in total
  1. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    [L44396] On July 21, 2023, maralixibat was also approved by Health Canada.[L47541] … [A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience.

  2. Drug

    Infliximab

    go.drugbank.com/drugs/DB00065
    ApprovedInvestigational

    There are currently two biosilimars of infliximab available in the US market that demonstrate a high degree of similarity to the reference product, Remicade. … Infliximab is produced by a recombinant cell line cultured by continuous perfusion.

    Products: INFLECTRA 100MG PLV F E KO, REMICADE 100MG PULV F E KO
  3. Drug

    Lacosamide

    go.drugbank.com/drugs/DB06218
    ApprovedInvestigational

    Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. … [A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008.

    Synonyms: (R)-2-acetamido-N-benzyl-3- methoxypropionamide, (+)-(2R)-2-(ACETYLAMINO)-N-BENZYL-3-METHOXYPROPANAMIDE
  4. Drug

    Xylitol

    go.drugbank.com/drugs/DB11195
    ApprovedInvestigational

    Xylitol is a non-fermentable sugar alcohol by most plaque bacteria, indicating that it cannot be fermented into cariogenic acid end-products [A32423]. … It works by inhibiting the growth of the microorganisms present in plaque and saliva after it accummulates intracellularly into the microorganism [A32423].

  5. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    [A236359] Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase … It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death.

  6. Drug

    Antipyrine

    go.drugbank.com/drugs/DB01435
    Approved

    An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver.

    Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic
  7. Drug

    Technetium Tc-99m tetrofosmin

    go.drugbank.com/drugs/DB09160
    Approved

    [A31592] Technetium Tc-99m tetrofosmin was developed by GE Healthcare and FDA approved on February 9, 1996. … The radioisotope, technetium-99m, is chelated by two 1,2-bis[di-(2-ethoxyethyl)phosphino]ethane ligands which belong to the group of diphosphines and which are referred to as tetrofosmin.

  8. Drug

    Capreomycin

    go.drugbank.com/drugs/DB00314
    ApprovedInvestigational

    Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.

  9. Drug

    Cabazitaxel

    go.drugbank.com/drugs/DB06772
    ApprovedInvestigational

    [A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376] … [A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010.

  10. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age … Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone